Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 6;13:1011858. doi: 10.3389/fimmu.2022.1011858

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Maldonado-Pérez, Tristán-Manzano, Justicia-Lirio, Martínez-Planes, Muñoz, Pavlovic, Cortijo-Gutiérrez, Blanco-Benítez, Castella, Juan, Wenes, Romero, Molina-Estévez, Marañón, Herrera, Benabdellah and Martin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

TCRKO CAR T cells maintain effector potency after highly repetitive tumor re-challenge. (A) Schema of second tumor re-challenge assay. CAR-T cells were co-cultured with Namalwa cells (E:T = 1:1) and rechallenged every day. (B) Graph showing number of remaining tumor cells quantified by flow cytometry every 24h. (C, D) Graph showing T cell (C) or CAR-T cells (D) fold expansion after every encounter relativized to the initial numbers of seeded cells. (E) Percentage of T_N/T_SCM +T_CM of WT ARI-0001 and TCRKO ARI-0001 after the different re-challenges with Namalwa cells. (F) Graph showing the percentage of PD1+TIM3+ cells in WT ARI-0001 and TCRKO ARI-0001 after the different re-challenges with Namalwa cells. Graphs show mean ± SEM of n=6 independent donors/group.